blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3458086

EP3458086 - SYNTHETIC MALARIA IMMUNOGENS, COMBINATIONS THEREOF, AND THEIR USE TO PREVENT AND TREAT MALARIA INFECTIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.05.2021
Database last updated on 16.09.2024
FormerRequest for examination was made
Status updated on  22.02.2019
FormerThe international publication has been made
Status updated on  25.11.2017
Most recent event   Tooltip28.05.2021Application deemed to be withdrawnpublished on 30.06.2021  [2021/26]
Applicant(s)For all designated states
The Trustees of The University of Pennsylvania
3160 Chestnut Street Suite 200
Philadelphia, PA 19104 / US
For all designated states
The Wistar Institute Of Anatomy And Biology
3601 Spruce Street
Philadelphia, Pennsylvania 19104 / US
For all designated states
Inovio Pharmaceuticals, Inc.
660 W. Germantown Pike
Suite 110
Plymouth Meeting, PA 19462 / US
For all designated states
ALY, Ahmed, S.I.
1324 Tulane Avenue
New Orleans, LA 70112 / US
[2019/13]
Inventor(s)01 / REUSCHEL, Emma
4411 Pine Street
Apt. 2R
Philadelphia, PA 19104 / US
02 / FERRARO, Bernadette
8594 Villa Jolla Drive, 376
La Jolla, CA 92037 / US
03 / ALY, Ahmed, S.I.
1324 Tulane Avenue
New Orleans, LA 70112 / US
04 / WEINER, David
717 Beacom Lane
Merion, PA 19066 / US
 [2019/13]
Representative(s)Leonard, Thomas Charles, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2019/13]
Application number, filing date17800274.719.05.2017
[2019/13]
WO2017US33617
Priority number, dateUS201662338841P19.05.2016         Original published format: US 201662338841 P
[2019/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017201454
Date:23.11.2017
Language:EN
[2017/47]
Type: A1 Application with search report 
No.:EP3458086
Date:27.03.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 23.11.2017 takes the place of the publication of the European patent application.
[2019/13]
Search report(s)International search report - published on:US23.11.2017
(Supplementary) European search report - dispatched on:EP26.06.2020
ClassificationIPC:A61K39/00, A61K39/002, A61K39/015, C07K14/445, C12N15/30
[2019/13]
CPC:
A61K39/015 (EP,KR,US); A61K38/208 (KR); A61K38/2086 (KR);
A61P33/06 (EP,KR,US); C07K14/445 (EP,KR,US); A61K2039/53 (EP,KR,US);
A61K2039/54 (KR); A61K2039/55527 (US); A61K2039/55538 (US);
C07K2319/02 (EP,US); C07K2319/20 (EP); C07K2319/42 (US);
C12N2800/107 (EP); C12N2800/22 (EP); Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/13]
TitleGerman:SYNTHETISCHE MALARIA-IMMUNOGENE, KOMBINATIONEN DARAUS UND DEREN VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON MALARIAINFEKTIONEN[2019/13]
English:SYNTHETIC MALARIA IMMUNOGENS, COMBINATIONS THEREOF, AND THEIR USE TO PREVENT AND TREAT MALARIA INFECTIONS[2019/13]
French:IMMUNOGÈNES SYNTHÉTIQUES DU PALUDISME, COMBINAISONS DE CEUX-CI ET LEUR UTILISATION POUR PRÉVENIR ET TRAITER LES INFECTIONS MALARIQUES[2019/13]
Entry into regional phase19.12.2018National basic fee paid 
19.12.2018Search fee paid 
19.12.2018Designation fee(s) paid 
19.12.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
19.12.2018Examination requested  [2019/13]
29.07.2019Amendment by applicant (claims and/or description)
26.01.2021Application deemed to be withdrawn, date of legal effect  [2021/26]
16.02.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/26]
Fees paidRenewal fee
28.05.2019Renewal fee patent year 03
21.05.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]US5814617  (HOFFMAN STEPHEN L [US], et al) [X] 1-3,5-10,12 * examples 3,4; claims 1,10 * [Y] 4,11;
 [XY]EP2385107  (PASTEUR INSTITUT [FR]) [X] 1-3,5-10,12 * figures 6-8,13,14; claims 3,5,14 * [Y] 4,11;
 [A]WO2015052543  (ISIS INNOVATION [GB], et al) [A] 1* SeqIdNo.3; SeqIdNo.6; Section 1.2.1;; tables 2.1,2.2 *;
    [ ] - "Part of Plasomodium yoelii PyHEP17 protein.", Geneseq, (19981126), Database accession no. AAW71319, URL: EBI, XP002796583 [ ] * sequence . *
 [Y]  - "CS protein consensus-IgE expression construct, SEQ 14.", Geneseq, (20120524), Database accession no. AZV16553, URL: EBI, XP002796584 [Y] 4,11 * sequence . *
    [ ] - "Synthetic construct DNA encoded protein SEQ:39.", Geneseq, (20111222), Database accession no. AZP30731, URL: EBI, XP002796585 [ ] * sequence . *
International search[A]US2010183590  (DRUILHE PIERRE [FR], et al) [A] 1, 2, 5, 6, 28, 31, 32, 46 * entire document *;
 [Y]US2011229514  (DOOLAN DENISE [AU], et al) [Y] 46 * entire document *;
 [A]WO2013082394  (UNIV CALIFORNIA [US], et al) [A] 1, 2, 5, 6, 28, 31, 32, 46* entire document *;
 [A]US8765145  (DRUILHE PIERRE [FR], et al) [A] 1, 2, 5, 6, 28, 31, 32, 46 * entire document *;
 [XY]WO2015052543  (ISIS INNOVATION [GB], et al) [X] 1, 2, 28 * entire document * [Y] 46
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.